aBLA Filing Intelligence & Biosimilar Opportunity

Elahere

Mirvetuximab Soravtansine-Gynx

Anticancer

Injection Injectable

Approval Date

14-Nov-22

Data Exclusivity Expiry

14-Nov-26

Market Exclusivity Expiry

14-Nov-34

Commercial snapshot

Market performance & projections

Revenue ($M)

690

CAGR (%)

0.2276

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

914

2027

1121

2028

1373

2029

1567

2030

1753

2031

1929

2032

2099

Molecule profile

Details & specifications

Molecule

Mirvetuximab Soravtansine-Gynx

Innovator

IMMUNOGEN, INC.

Dosage Form

Injection Injectable

Strength

100 mg/20 mL single-dose vial

Therapeutic Category

Anticancer

Usage

To treat patients with recurrent ovarian cancer that is resistant to platinum therapy

Good to know

Frequently asked questions

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.

Why Spring Bio Solution

Intelligence you can file on

Verified regulatory data

Milestones tracked against primary FDA sources and refreshed continuously.

Analyst-built projections

Seven-year sales outlooks modeled by our pharma intelligence team.

First-to-file focus

Exclusivity windows framed around the decisions generics teams actually make.

Partnership on demand

From API sourcing to dossier support — one request starts the conversation.